Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 17/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.61 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.59 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.59 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.59 |
| ▸ | MMP1 | P03956 | 1/20 | 0.59 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.59 |
| ▸ | ACHE | P22303 | 1/20 | 0.59 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.59 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17092806 | 0.98 | TOP1 (0.72) | TOP1MEN1KMT2ASLC2A1 | |
| SCHEMBL17092799 | 0.96 | TOP1 (0.74) | TOP1MEN1KMT2ASLC2A1 | |
| SCHEMBL17092798 | 0.93 | TOP1 (0.70) | TOP1MEN1KMT2ASLC2A1 | |
| SCHEMBL17092803 | 0.93 | TOP1 (0.69) | TOP1MEN1KMT2ASLC2A1 | |
| SCHEMBL5649602 | 0.91 | TOP1 (0.81) | TOP1MEN1KMT2A | |
| SCHEMBL27829924 | 0.91 | TOP1 (0.81) | TOP1MEN1KMT2A | |
| SCHEMBL9559783 | 0.88 | TOP1 (0.81) | TOP1MEN1KMT2A | |
| SCHEMBL17092812 | 0.88 | TOP1 (0.62) | TOP1MEN1KMT2ASLC2A1 | |
| SCHEMBL23255613 | 0.87 | TOP1 (0.87) | TOP1SLC2A1 | |
| SCHEMBL17092808 | 0.87 | TOP1 (0.74) | TOP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2912039-B1 | DERIVATIVES OF CAMPTOTHECIN, A METHOD OF PRODUCING THEM AND THEIR USE | INST CHEMII ORGANICZNEJ POLSKIEJ AKADEMII NAUK (PL) | 2017-07-12 | — | — | EP | claimed |
| US-9682992-B2 | Derivatives of camptothecin, a method of producing them and their use | INSTYTUT CHEMII ORGANICZNEJ POLSKIEJ AKADE (PL) | 2017-06-20 | — | — | US | claimed |
| US-20150266888-A1 | DERIVATIVES OF CAMPTOTHECIN, A METHOD OF PRODUCING THEM AND THEIR USE | NARODOWY INSTYTUT LEKÓW (PL) | 2015-09-24 | — | — | US | claimed |
| EP-2912039-B1 | DERIVATIVES OF CAMPTOTHECIN, A METHOD OF PRODUCING THEM AND THEIR USE | INST CHEMII ORGANICZNEJ POLSKIEJ AKADEMII NAUK (PL) | 2017-07-12 | — | — | EP | disclosed |
| US-9682992-B2 | Derivatives of camptothecin, a method of producing them and their use | INSTYTUT CHEMII ORGANICZNEJ POLSKIEJ AKADE (PL) | 2017-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266888-A1 | DERIVATIVES OF CAMPTOTHECIN, A METHOD OF PRODUCING THEM AND THEIR USE | TOP2A, TOP2B, MCL1 | TOP1 4/4885MEN1 1392/4885KMT2A 3599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.